OPKO Health, Inc. (NASDAQ: OPK), announces that in connection with the acquisition of Transition Therapeutics Inc., Canadian securities regulation will deem OPKO to be a reporting issuer in the provinces in which Transition was a reporting issuer, unless OPKO applies for an order that those rules do not apply to it on the basis that less than 2% of its shareholders reside in Canada. As OPKO has a very small number of shareholders in Canada, it will be applying for an order that it not be a reporting issuer in any jurisdiction of Canada.

About OPKO Health, Inc.

OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency, and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner Tesaro and IV formulation PDUFA is January 2017). Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), a long-acting Factor VIIa drug for hemophilia (in Phase 2a) and a long acting oxyntomodulin for diabetes and obesity (in Phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at www.opko.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding OPKO’s application to cease to be a reporting issuer in Canada. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

OPKO Health, Inc.Tara Mackay, 305-575-4100Investor RelationsorMediaRooney & AssociatesTerry Rooney, 212-223-0689trooney@rooneyco.comorMarion Janic, 212-223-4017mjanic@rooneyco.comorInvestorsLHAAnne Marie Fields, 212-838-3777afields@lhai.comorBruce Voss, 310-691-7100bvoss@lhai.com

Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Opko Health Charts.
Opko Health (NASDAQ:OPK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Opko Health Charts.